Europe's drug regulator on May 22 recommended approval for the once-daily oral Wegovy ↗ 25 mg tablet, for adults with obesity or excess weight plus at least one weight-related condition. The Committee for Medicinal Products for Human Use, the European Medicines Agency's scientific committee whose positive opinion is the last review step before European Commission sign-off, said the pill should be authorized to reduce body weight and to maintain that reduction long-term. The label the CHMP recommended includes the cardiovascular outcomes from SELECT, the trial that documented a 20 percent reduction in major heart events with injectable Wegovy in patients with established heart disease and overweight or obesity.

This is the first oral GLP-1 receptor agonist that Europe has recommended for weight management. Oral semaglutide in its smaller 7 to 14 mg doses was already approved in Europe for type 2 diabetes under the Rybelsus brand. The 25 mg dose for obesity, branded as Wegovy in pill form, is a new label.

The number the dossier was anchored on

The data package the CHMP weighed was built on OASIS 4, Novo Nordisk's Phase 3 trial of the 25 mg pill in adults with obesity or excess weight plus a comorbidity. Patients on the pill lost a mean 16.6 percent of body weight against placebo. That number sits in the same range as the roughly 15 percent mean weight loss recorded for injectable Wegovy 2.4 mg in STEP 1, the obesity registrational trial that anchored the injectable's 2021 approval. A 240-pound patient on either formulation would end the trial period somewhere around 36 to 40 pounds lighter, on average. The two trial means are not a controlled head-to-head, but the regulators considered them close enough that pill and injection enter the European market with comparable efficacy framing.

What the SELECT carryover changes

The bigger commercial story is what the label keeps from the injectable. SELECT, reported in 2023, was the cardiovascular outcomes trial that randomized 17,604 patients with established cardiovascular disease plus overweight or obesity, without diabetes, to injectable semaglutide ↗ 2.4 mg or placebo. The result was a 20 percent reduction in the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke. That hazard ratio is what pushed cardiology guideline writers to treat injectable Wegovy as a cardiovascular drug as well as a weight-loss drug. The CHMP recommendation carries that label language onto the pill. For a prescriber in Madrid or Berlin, the pill arrives already badged as a heart-event-reducing drug for the SELECT population, not just a weight tool.

The clinical caution that surrounds carrying outcomes data from one formulation to another is real. SELECT itself was run with injectable Wegovy. The pill has not been tested in its own cardiovascular outcomes trial. The CHMP's reading is that the molecule and the systemic exposure are equivalent enough between the two formulations that the cardiovascular benefit travels with the molecule, not with the syringe. That is a regulator's call, not a trialist's, and the post-authorization safety study Novo will run after launch is where the assumption gets stressed against real-world data.

The launch sequence

Novo plans to launch the pill in select non-US markets in the second half of 2026, with the United Kingdom, Germany, and Denmark previously flagged as the first international launches. The European launch follows the US ramp that began in early 2026 and has put the pill at roughly twenty times the weekly prescription volume of Lilly's competing oral small-molecule GLP-1 (the orforglipron tablet branded as Foundayo). The American volume curve has been the supply test. The European launch is the indication-and-label test, in markets whose national health systems reimburse obesity treatment on tighter cost-effectiveness criteria than US payers do.

Pricing has not been published. European obesity-market pricing is closely held until each national reimbursement authority finishes its negotiation, which can extend an actual pharmacy launch by quarters even after the regulator has signed off. The Wegovy injectable took roughly 18 months from EU approval to broad reimbursement across the three lead launch countries.

Platform note

Semaglutide ↗ is an acylated 31-amino-acid analog of native GLP-1, with a fatty-acid sidechain that lets it bind albumin and survive in circulation long enough for once-weekly injection. The pill solves a different problem. It pairs that same peptide with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, an absorption enhancer commonly called SNAC that opens a window of high local pH in the stomach lining where the peptide can cross into circulation before pepsin and the other gastric proteases finish it. The chemistry is why the 25 mg oral dose is roughly twenty times the injectable dose. Most of the swallowed drug is destroyed before it reaches the bloodstream, and the dose has to be sized to what little gets across. The GLP-1R target page ↗ carries the receptor-level mechanism that both formulations share once the molecule does reach the receptor.